Ersentilide

Drug Profile

Ersentilide

Alternative Names: CK 3579; HE 93

Latest Information Update: 19 Nov 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer Bayer HealthCare Pharmaceuticals; Helopharm
  • Class Class III antiarrhythmics; Imidazoles; Propanolamines; Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor antagonists; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Arrhythmias

Most Recent Events

  • 19 Nov 1998 A preclinical study has been added to the pharmacodynamics section
  • 02 Sep 1998 No-Development-Reported for Arrhythmias in Canada (Unknown route)
  • 02 Sep 1998 No-Development-Reported for Arrhythmias in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top